Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke

Recruiting

Phase N/A Results N/A

Trial Description

The purpose of this study is to determine the safety and feasibility of remote limb ischemic conditioning(RIC) in acute ischemic stroke patients who received r-tPA thrombolytic therapy.

Conditions

Interventions

  • Remote Ischemic Conditioning Device
    Other Names: RIC
    Intervention Desc: In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Doctormate, IPC-906
    ARM 1: Kind: Experimental
    Label: RIC group
    Description: The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.

Outcomes

Type Measure Time Frame Safety Issue
Primary Feasibility of RIC after acute ischemic stroke 7 days
Secondary Objective signs of tissue or neurovascular injury within 7(±24h) days
Secondary Number of participants with intracranial hemorrhage in two groups 7(±24h)days
Secondary Scores assessed by National Institutes of Health Stroke Scale(NIHSS) 7(±24h)days
Secondary The functional outcome at 90 days assessed by modified Rankin scale (mRS). 90( ±7days) days
Secondary functional outcome assessed by Barthel Index(BI) 90( ±7days)days
Secondary cerebral infarct volume. 3-7 days after stroke onset
Secondary Cardiovascular parameters during 7 days of RIC treatment. 7 days
Secondary the heart rate during 7 days of RIC treatment. 7 days
Secondary Levels of plasma myoglobin baseline and 7(±2)days
Secondary Levels of serum IL-6 baseline and 7(±2)days
Secondary Levels of serum HS-CRP baseline and 7(±2)days
Secondary Levels of serum HCY baseline and 7(±2)days
Secondary Any adverse events 90(±7)days

Sponsors